Kristina S Yu

发表

Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada

K. Savage, C. Lilley, Jingmin Liu, 2023, Advances in therapy.

Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial

J. Burke, T. Phillips, M. Fanale, 2023, Leukemia & lymphoma.

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy

J. Burke, T. Phillips, M. Fanale, 2023, The oncologist.

Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study

A. Evens, S. Parsons, M. Fanale, 2023, JCO oncology practice.

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database

M. Fanale, A. Surinach, A. Winter, 2022, Blood.

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

J. Burke, T. Phillips, M. Fanale, 2021, Blood.

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

J. Burke, T. Phillips, M. Fanale, 2021, Blood.

Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada

A. Kansal, D. Zou, Wen-Qing Ma, 2022, Journal of medical economics.

Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial

J. Burke, T. Phillips, B. Bloudek, 2023, Journal of managed care & specialty pharmacy.

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

M. Fanale, A. Surinach, A. Winter, 2022, Blood.

Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.

M. Fanale, A. Surinach, A. Winter, 2023, Clinical lymphoma, myeloma & leukemia.

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

A. Evens, S. Parsons, M. Fanale, 2021, Blood.